66th ASH Annual Meeting: 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

Symposia: Cellular Immunotherapies other than CAR-T Cells: Basic and Translational Oral and Poster Abstracts
Poster

Research, Acute Myeloid Malignancies, Combination therapy, AML, Fundamental Science, Drug development, Translational Research, Assays, Plasma Cell Disorders, CML, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Biological Processes, Myeloid Malignancies, Technology and Procedures, Natural Killer (NK) Cell Therapies

Halls G-H (San Diego Convention Center)

2054

Discovery of JNJ-89853413, a First-in-Class CD33xVδ2 T-Cell Engager for the Treatment of Acute Myeloid Leukemia

Sara El Ashkar, PhD¹, Lorena Kallal²^*, Kavita Raman²^*, Ranjeet Prasad Dash²^*, Nirav Shah²^*, Lore Delbroek¹^*, Lénárd Kertész¹^*, Heleen Van Acker¹^*, Steffie Junius¹^*, Ivo Cornelissen¹^*, Surendar Arumugam¹^*, Lauren Gerloff²^*, Kathryn Bradford²^*, E. Christine Pietsch, PhD³, Leopoldo Luistro, PhD²^*, Bethany Mattson, PhD²^*, Christina Guttke, PhD⁴^*, Karim Safer²^*, Janine Arts, PhD⁵^*, Sonal Patel, PhD⁶^* and Ulrike Philippar, PhD¹

¹Janssen Research & Development, Beerse, Belgium
²Janssen Research & Development, Spring House, PA
³Janssen Research and Development, Spring House, PA
⁴Janssen Research & Development, LLC, Spring House, PA
⁵Janssen Scientific Innovation Oncology, Beerse, Belgium
⁶Janssen Scientific Innovation Oncology, London, United Kingdom

2055

CIB315: An Allogeneic, Off-the-Shelf Anti-GPRC5D iPSC-Derived CAR-NK Product Targeting Multiple Myeloma

Jiayin Yang, PhD^1,2, Lixiang Jiang²^*, Zhibin Zhu²^*, Yubo Yan²^*, Jian Fu²^* and Mingjun Wei²^*

¹Cell Inspire Therapeutics, Shenzhen, China
²Cell Inspire Biotechnology, Shenzhen, China

2056

Developing Novel Cell Therapy Strategies to Convert Macrophage Programming and Induce Synergistic, Multicellular Immunity Against AML

Ryma Toumi, PhD¹^*, Simonne Guenette¹^*, Edison Chiu²^*, Aitong Ruan¹^*, Shannon Oda, PhD¹ and Amber Alcorn¹^*

¹Seattle Children's Research Institute, Seattle, WA
²Seattle Children's Research Institute, seattle, WA

2057

Tumor-Primed CD3⁺CD56⁺natural Killer T-like Cells As an Efficient Novel Cell Therapy for Relapsed/Refractory Multiple Myeloma

Ji Hyun Lee, MD, PhD¹, Seok-Ho Kim²^*, Junsang Doh³^*, Duck Cho⁴^*, Jeong-a Kim²^*, Sung Yong Oh⁵^*, Sung-Hyun Kim, MD⁶^* and Juheon Lee²^*

¹Dong-A University College of Medicine, Busan, South Korea
²Department of Health Sciences, The Graduate School of Dong-A University, Busan, Korea, Republic of (South)
³Department of Materials Science and Engineering, College of Engineering, Seoul National University, Seoul, Korea, Republic of (South)
⁴Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)
⁵Dong-A University Hospital, Busan, Korea, Republic of (South)
⁶Department of Internal Medicine, Dong-A University Medical Center, Busan, Korea, Republic of (South)

2058

Development of a Novel Allogeneic Super-Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors

Hanlu Wang¹^*, Li Liu¹^*, Chao Zhang¹^*, Junxiao Gao¹^*, Lulu Lv, PhD²^* and Li Zhou, MD¹^*

¹Juventas Cell Therapy Ltd., Shanghai, China
²Juventas Cell Therapy Ltd, Tianjin, China

2059

Venetoclax Enhances Human Γδt Cells Anti-Leukemia Immunity through Metabolic Reprogramming

Chen Xingchi^1,2,3^*, Guangyu Sun^1,2,3^*, Yinqiang Sui⁴^*, Weiwei Ma⁴^*, Yonghui Zhang^5,6^* and Xiaoyu Zhu^1,2,3

¹Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China
²Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China
³Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
⁴UnicetBio.Co.,Ltd, Beijing, China
⁵Tsinghua-Peking Center for Life Sciences, State Key Laboratory of Membrane Biology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
⁶Tsinghua-Peking Center for Life Sciences, School of Pharmaceutical Science,Tsinghua University, Beijing, China

2060

Bispecific T Cell Engager with Trbc-Targeting Antibody Against Effector T Cells for the Treatment of T Cell Malignancy

Tsubasa Chikada¹^*, Hikari Asano, MS¹^*, Madoka Terashima, MS¹^*, Toshiyuki Tsuchiya, PhD¹^*, Yuuma Kabumoto, MS¹^*, Go Okita, MS¹^*, Toshiaki Takahashi, MS¹^*, Hiroshi Nakakubo, PhD¹^*, Ryouko Mieno, MS²^*, Yuji Ito, MS²^*, Takayoshi Fukushima, MS²^* and Yoji Ishida, MD¹

¹Shinkiba Laboratory, Meiji Seika Pharma Co., Ltd, Tokyo, Japan
²Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Kanagawa, Japan

2061

Polb 001, an Oral p38 MAPK Inhibitor, Reduces Cytokine Release Syndrome (CRS) in a Mouse Model of Immunotherapy-Induced CRS

Liam Tremble, PhD, MSc, BSc¹^*, Paula Maguire, PhD¹^*, Jiwon Yang, PhD²^*, James G Keck³^*, Laura Maher¹^*, Mark Graham⁴^*, Martin F Kaiser, MD^5,6, Emma Searle, MD, PhD⁷^* and Mark Sumeray, MD¹^*

¹Poolbeg Pharma, Dublin, Ireland
²Innovation & Product Development, The Jackson Laboratory, Sacramento, CA
³Innovation & Product Development, The Jackson Laboratory Sacramento, Sacramento, CA
⁴MG Toxicology Consultancy, Leicestershire, United Kingdom
⁵The Royal Marsden NHS Foundation Trust, London, United Kingdom
⁶The Institute of Cancer Research, Sutton, United Kingdom
⁷The Christie NHS Foundation Trust, Manchester, United Kingdom

2062

Vididencel, a Leukemia-Derived Dendritic Cell Vaccine, Acts Synergistically with Azacitidine/Venetoclax Treatment in a Preclinical AML Model

Haoxiao Zuo, PhD¹^*, Calum Leitch, PhD^2,3^*, Jorn Kaspers, MSc¹^*, Mihaela Popa, DVM^2,3^*, Alex Karlsson-Parra, MD, PhD¹^*, Erik Manting, PhD¹^*, Jeroen Rovers, MD, PhD¹^*, Bjorn T. Gjertsen, MD^4,5,6, Emmet McCormack, PhD^2,5,7^* and Satwinder Kaur Singh, PhD⁸^*

¹Mendus AB, Stockholm, Sweden
²Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
³KinN Therapeutics AS, Bergen, Norway
⁴KG Jebsen Centre for Myeloid Blood Cancer CMYC, University of Bergen, Bergen, Norway
⁵Department of Medicine, Hematology section, Haukeland University Hospital, Bergen, Norway
⁶Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
⁷Centre for Pharmacy, Department of Clinical Science, University of Bergen, Bergen, Norway
⁸Mendus AB, Stockholm, AL, Netherlands

2063

Optimizing Chimeric Antigen Receptor Endodomains for Effector Function and Cell Expansion in iPSC-Derived T-Cell Therapies

Chris Dower, Ph.D.^*, Sean Heron^*, Andrew Devaney, M.S.^*, John Wheeler, Ph.D.^*, Amanda Naso, B.S.^*, Wisam Mohamed, M.S.^*, Michael Naso, Ph.D.^* and Jill Carton^*

Century Therapeutics, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703.P1.34 703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I